Ontology highlight
ABSTRACT:
SUBMITTER: Serrao E
PROVIDER: S-EPMC2660292 | biostudies-literature | 2009 Mar
REPOSITORIES: biostudies-literature
Serrao Erik E Odde Srinivas S Ramkumar Kavya K Neamati Nouri N
Retrovirology 20090305
Merck's MK-0518, known as raltegravir, has recently become the first FDA-approved HIV-1 integrase (IN) inhibitor and has since risen to blockbuster drug status. Much research has in turn been conducted over the last few years aimed at recreating but optimizing the compound's interactions with the protein. Resulting me-too drugs have shown favorable pharmacokinetic properties and appear drug-like but, as expected, most have a highly similar interaction with IN to that of raltegravir. We propose t ...[more]